XM does not provide services to residents of the United States of America.
C
C

Clariant

News

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T

Belgium's Syensqo on track for worst day ever after top end forecast cut

UPDATE 3-Belgium's Syensqo on track for worst day ever after top end forecast cut Annual EBITDA seen in 1.4 bln to 1.475 bln euros range Q2 EBITDA 378 mln euros vs. 383 mln euros consensus Updates share move, adds Syensqo and JPM comments By Alban Kacher and Leo Marchandon Aug 1 (Reuters) - Syensqo's SYENS.BR shares fell 6% on Thursday after the company lowered the top end of its annual core profit and free cash flow forecast, as it does not expect a broader demand recovery in the final six mont
C
S

Bodycote, Croda, Spectris

EUROPE RESEARCH ROUNDUP- Bodycote, Croda, Spectris July 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bodycote, Croda and Spectris, on Wednesday. HIGHLIGHTS * Bodycote Plc BOY.L : HSBC cuts target price to 940p from 950p * Bucher Industries AG BUCN.S : Berenberg cuts target price to CHF 464 from CHF 470 * Croda CRDA.L : HSBC cuts target price to 4400p from 4800p * Spectris Plc SXS.L : JP Morgan raises target price to 2,950p fr
A
A
A
B
B
B
C
C
C
C
D
D
E
E
G
G
H
I
L
S
S
S
A
D
F
I
I
P

Clariant falls after it trims sales guidance

BUZZ-Clariant falls after it trims sales guidance ** Shares of Clariant CLN.S fall around 6% after the Swiss speciality chemicals maker trimmed its sales growth outlook citing uncertainties in its catalyst business ** It now expects a flat to low single-digit percent sales growth vs low single-digit sales growth it had forecast earlier ** "Investor
C

Clariant Raises 2024 Margin Target To Around 16%

BRIEF-Clariant Raises 2024 EBITDA-Margin Target To Around 16% July 30 (Reuters) - CLARIANT AG CLN.S : CLARIANT DELIVERS STRONG UNDERLYING MARGIN IMPROVEMENT IN THE SECOND QUARTER AND INCREASES 2024 PROFITABILITY OUTLOOK TO ~ 16 % EBITDA MARGIN MEDIUM-TERM TARGETS CONFIRMED OUTLOOK 2024: FLAT TO LOW SINGLE-DIGIT PERCENT SALES GROWTH IN LOCAL CURRENC
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.